Abstract:Background: Altered proteome profiles have been reported in both postmortem brain tissues and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with AD pathology, amyloid pathology, and tau-related neurodegeneration have not yet been fully explored. Using a robust automated MS-based proteomic biomarker discovery workflow, we measured cerebrospinal fluid (CSF) proteomes to explore their association with well-established markers of core AD pathology. Methods: Cross-sectional analysis was performed on CSF collected from 120 older community-dwelling adults with normal (n = 48) or impaired cognition (n = 72). LC-MS quantified hundreds of proteins in the CSF. CSF concentrations of β-amyloid 1-42 (Aβ1-42), tau, and tau phosphorylated at threonine 181 (P-tau181) were determined with immunoassays. First, we explored proteins relevant to biomarker-defined AD. Then, correlation analysis of CSF proteins with CSF markers of amyloid pathology, neuronal injury, and tau hyperphosphorylation (i.e., Aβ1-42, tau, P-tau181) was performed using Pearson's correlation coefficient and Bonferroni correction for multiple comparisons. Results: We quantified 790 proteins in CSF samples with MS. Four CSF proteins showed an association with CSF Aβ1-42 levels (p value ≤ 0.05 with correlation coefficient (R) ≥ 0.38). We identified 50 additional CSF proteins associated with CSF tau and 46 proteins associated with CSF P-tau181 (p value ≤ 0.05 with R ≥ 0.37). The majority of those proteins that showed such associations were brain-enriched proteins. Gene Ontology annotation revealed an enrichment for synaptic proteins and proteins originating from reelin-producing cells and the myelin sheath. Conclusions: We used an MS-based proteomic workflow to profile the CSF proteome in relation to cerebral AD pathology. We report strong evidence of previously reported CSF proteins and several novel CSF proteins specifically associated with amyloid pathology or neuronal injury and tau hyperphosphorylation.

Advances in Studies on Proteomics in Alzheimer Disease

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Characterization of proteome of human cerebrospinal fluid.

Subcellular proteomics insights into Alzheimer's disease development

Advances in the study on Alzheimer's disease proteomics

Advances of Mass Spectrometry Based Proteomics in Biomarker Research in Neurodegenerative Diseases

Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery

The research progress of quantitative proteomics in clinical biomarker discovery in Alzheimer's disease

Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies

Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases

The progress in the proteomics researches of central nervous system diseases and drugs

Progress of Clinical Laboratory Tests and Molecular Imaging for Diagnosis of Alzheimer's Disease

Advances in Proteomics Allow Insights Into Neuronal Proteomes

P3‐054: Biomarkers for Early Detection of Alzheimer's Disease: Plasma Proteomic Study of Early to Mild Stages of Alzheimer's Disease

Alzheimer disease pathology and the cerebrospinal fluid proteome

Difference of proteomic protein in brains between amyloid protein precursor transgenic mice and normal mice

Potential prognostic value of CSF-targeted proteomics across the Alzheimer's disease continuum

Multiplex Cerebrospinal Fluid Proteomics Identifies Biomarkers for Diagnosis and Prediction of Alzheimer’s Disease

Difference of proteomic protein expression in brains between amyloid protein precusor transgenic mice and normal mice